Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Institute Report
Understanding Medicine Spending in Australia
Trends and dynamics in healthcare and medicine spending
Jul 15, 2020
To download files you must give consent to process your personal data by clicking the "Accept" button below.

About the Report

This report focuses on the current and historic levels of spending on medicines in Australia. As government data suggest healthcare and medicine spending is rising, an enhanced understanding of the drivers of those trends can better inform policy. The report provides unique views of IQVIA data alongside official government statistics to provide context and clarity to these important issues.

Report Summary

The report analyzes pharmaceutical spending trends in Australia and includes comparisons to spending in other healthcare sectors. In particular, the report examines the Pharmaceutical Benefit Scheme (PBS) and pharmaceutical sector spending. While overall healthcare spending has grown 5% on a CAGR basis between 2010 and 2018, net PBS spending on pharmaceuticals decreased from 8% to 5% of total healthcare spending in this period. The report also presents analyses of the impact of rebates, brand volume, and price on spending, as well as a view of per capita revenue and net spending. In the period from 2010 to 2019, pharmaceutical net revenues remained relatively flat with the launch of new brands driving spending and price events as the largest negative driver of growth. Net pharmaceutical revenues and PBS spending have remained constant on an adjusted per capita basis capita basis, at an average just over $1 per day, compared to steadily increasing spending on hospital and medical, which is currently averaging over $13 per day per person in Australia.

Key Findings


The majority of net healthcare spending is on hospital and medical services, while PBS net spending has declined from 8% to 5% since 2010.

Historical Percentage of Overall Net Healthcare Spending by Sector, Fiscal Years 2010–2018, AU$Bn

  • Australia’s net healthcare spending has increased from $121.5 billion to $183.1 billion in fiscal year from 2010 to 2018.
  • Hospital and medical services represent the largest percentage of net healthcare spending, realizing costs of $124 billion in fiscal year ending 2018, while PBS net pharmaceutical spending has declined from 8% to 5% of net healthcare spending.
  • All other medicines spending has remained a constant share of net healthcare spending at 6%.

 

Total non-discounted revenue from pharmaceuticals has risen over the past 10 years, but remains flat when accounting for rebates.

Total Non-Discounted Revenue, Rebates and Reported Net Spending for Fiscal Years 2010–2019, AU$Bn

  • Over the last 10 years, total non-discounted revenue from pharmaceuticals has increased 25.9%, reaching just over $12.0 billion in fiscal year 2019.
  • However, net revenues have remained relatively constant over the ten-year period after accounting for rebates, which have risen from $9.3 billion to $9.8 billion — a 5% increase since fiscal year 2010.

 

Pharmaceutical spending growth is largely flat after accounting for rebates, and is driven by protected brand volume and new brands, offset by price events.

Brand Volume, New Brands, and Net Price Contributions to Growth, Fiscal Years 2010–2019, AU$Bn

  • Price events have been the largest negative driver of growth in the period, with a peak of -$2,274 billion in fiscal year ending 2017. This corresponds to CAGRs of -22.3% over a five-year period, and -17.3% over a nine-year period.
  • Protected brand volume remains a strong positive contributor to growth especially in 2016 and 2017.
  • As a result of the negative contribution of price events in fiscal years ending 2013, 2014, 2015 and 2017, total pharmaceutical spending growth declined despite the positive contribution of growth by new brands.

 

Net pharmaceutical revenues and PBS spending have remained constant on an adjusted per capita basis averaging slightly over $1 per day.

Historical Real Net Per Capita PBS Spending, Revenues, and GDP, Fiscal Years 2010–2018, AU$ 2019$

  • On an adjusted per capita basis capita basis, Australians pay just over AUD $1 per day for access to PBS medicines.
  • Spending on PBS medicines was $390 in 2019, which was up 6% from a low of $366 in 2010.
  • Both per capita net PBS spending and per capita net pharmaceutical revenues account for 0.7%, respectively, of total per capita GDP in fiscal year 2018, a decline from 0.9% in fiscal year 2010.
Contact Us